Bulgaria - búlgaro - БАБХ (Българска агенция по безопасност на храните)

Асклеп- фарма ООД - Албендазол - перорална суспензия - 100 mg/ml - говеда, овце

Bulgaria - búlgaro - БАБХ (Българска агенция по безопасност на храните)

interchemie werken de adelaar b.v. - Левамизола хидрохлорид, oxyclozanide - перорална суспензия - 30 mg/ml, 60 mg/ml - говеда, овце

Unión Europea - búlgaro - EMA (European Medicines Agency)

merial - eprinomectin - ендектоцидите - Говеда - Лечение на следните паразити: - чревни нематоди (за възрастни и Л4):- ostertagia ostertagi/лировидный, cooperia oncophora/surnabada, с. punctata, че haemonchus contortus, носител на axei, Т. colubriformis, bunostomum phlebotomum, nematodirus helvetianus, oesophagostomum radiatumlungworm (възрастни и Л4):- dictyocaulus viviparuswarbles (паразитни стадии):- гиподермы бовис, ч. lineatummange кърлежи:- болест на sarcoptes var. Бовис вшивость: linognathus vituli, haematopinus eurysternus, solenoptes capillatushorn мухи: haematobia irritansprevention повторно заразяване със следните паразити:- dictyocaulus живородка, ostertagia ostertagi/лировидный, носител на colubriformis, haemonchus contortus, и bunostomum phlebotomum;- oesophagostomum radiatum, cooperia oncophora/surnabada, с. punctata и носител на axei.

Unión Europea - búlgaro - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Антинеопластични средства - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Unión Europea - búlgaro - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - Карцином, недребноклетъчен белодроб - Антинеопластические и имунномодулиращи агенти, моноклонални антитела - nivolumab bms е показан за лечение на локално напреднал или метастазирал сквамозен недребноклетъчен рак на белия дроб (nsclc) след предшестваща химиотерапия при възрастни.

Unión Europea - búlgaro - EMA (European Medicines Agency)

pfizer europe ma eeig - crizotinib - Карцином, недребноклетъчен белодроб - Антинеопластични средства - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Unión Europea - búlgaro - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - Ваксини - Активна имунизация срещу болест, причинена от streptococcus pneumoniae серотипове 4, 6b, 9v, 14, 18 c, 19е и 23f (включително сепсис, менингит, пневмония, бактериемия и остър отит) при бебета и деца от два месеца до пет години на възраст. Използването на Превенар трябва да се определя въз основа на официални препоръки, като се вземе предвид влиянието на инвазивни заболявания в различните възрастови групи, както и променливостта на серотип на епидемиологията в различни географски райони.

Unión Europea - búlgaro - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - Неоплазми на гърдата - Антинеопластични средства - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Unión Europea - búlgaro - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - Стомашно-чревни стромални тумори - Антинеопластични средства - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Unión Europea - búlgaro - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - анти-туморни агенти - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.